Exkivity (mobocertinib) is used to treat a specific type of advanced non-small cell lung cancer (NSCLC) in adults. It was given accelerated approval and is the first FDA-approved medication for this condition that's available in a convenient oral capsule. But the medication should only be used if first-choice treatments haven't worked. Side effects include diarrhea, vomiting, and rash.
Note: Exkivity (mobocertinib) is no longer available in the United States as the manufacturer as voluntarily withdrawn it from the market.
Locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations in people who have previously had chemotherapy
Exkivity (mobocertinib) works by blocking tyrosine kinases in cancer cells. Tyrosine kinases are proteins that tell cancer cells to grow and divide. By stopping these proteins, Exkivity (mobocertinib) helps treat NSCLC by aiming to slow down cancer growth.
Source: DailyMed
By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.